The investment community’s appetite for the cannabis sector is transitioning from high-cost cultivation and extraction businesses to companies using clinical data to tailor products for specific conditions, an audience has been told.

Join the Cannabiz revolution

Want to stay ahead of the cannabis curve with the latest local and international news, analysis and intelligence and access to Australia's legal cannabis industry?

This article is included with our Premium subscription.

Speaking at an investor session hosted by Proactive, Zelira Therapeutics CEO Dr Richard Hopkins said lower capex, higher margin companies focused on patient outcomes “represent the future” and would attract more sophisticated funds into the sector.

Prior to launching Cannabiz, Martin was co-founder and CEO of Asia-Pac’s leading B2B media and marketing information brand Mumbrella, overseeing its sale to Diversified Communications in 2017. A journalist...